Skip to main content

Drug Interactions between amifostine and Avapro

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

amifostine irbesartan

Applies to: amifostine and Avapro (irbesartan)

MONITOR: Concomitant use with antihypertensive agents or drugs with hypotensive effects may increase the risk and severity of hypotension associated with amifostine. Hypotension has been reported frequently in patients treated with amifostine. It is usually transient (lasting from 5 to 15 minutes) and closely associated with amifostine administration, but may persist or become evident hours after administration. Moreover, hypotension can occur despite adequate hydration and positioning of the patient. Significant drops in systolic blood pressure have been reported, in some cases resulting in premature termination of amifostine infusion. In rare cases, sometimes during or after hypotension, patients have experienced tachycardia, bradycardia, dyspnea, apnea, hypoxia, chest pain, myocardial ischemia, renal failure, myocardial infarction, convulsions, unconsciousness, respiratory arrest, and cardiac arrest.

MANAGEMENT: If medically feasible, antihypertensive medications should be interrupted 24 hours prior to amifostine administration. Blood pressure should be closely monitored during and after treatment. In addition to hypotension, transient hypertension or exacerbation of preexisting hypertension may occur from intravenous hydration, discontinuation of antihypertensive medications, or other causes. Patients who continue their hypotensive medication(s) during amifostine therapy should be carefully monitored for the development of hypotension. Clinical symptoms of hypotension are usually quickly reversed by fluid infusion and postural management.

References (2)
  1. (2001) "Product Information. Ethyol (amifostine)." Alza
  2. (2002) "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc

Drug and food interactions

Moderate

irbesartan food

Applies to: Avapro (irbesartan)

GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.

MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.

References (2)
  1. (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
  2. (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.